Lercanidipin-Omniapharm Recordati Pharma Gmbh (Lercanidipine Hydrochloride)

• Lercanidipine is a calcium channel blocker used in the management of hypertension, a condition characterized by elevated arterial pressure.
• Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.
• Isolated systolic hypertension: provides long‑term blood pressure control in patients with predominant systolic elevation.

• Lercanidipine selectively inhibits L-type calcium channels in vascular smooth muscle cells, preventing calcium influx that is necessary for contraction. This inhibition leads to relaxation of arterial smooth muscle, resulting in vasodilation and a consequent reduction in peripheral vascular resistance, which lowers systemic blood pressure.

Lercanidipine may be associated with a range of adverse reactions, which are categorized by frequency.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: warmth and redness, typically occurring shortly after dosing.
• Peripheral edema: swelling of ankles or lower legs.
• Dizziness or light‑headedness: especially when standing quickly.
• Tachycardia: increased heart rate in some patients.
• Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Myocardial infarction: rare occurrence of heart attack.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Allergic reactions: rash, pruritus, or angioedema.
• Cardiac arrhythmias: irregular heart rhythms in susceptible individuals.

• When prescribing or dispensing lercanidipine, several safety considerations should be observed.
• Blood pressure monitoring: regularly assess to avoid excessive hypotension.
• Dose titration: start with a low dose and adjust gradually based on response.
• Hepatic impairment: use with caution in patients with liver dysfunction.
• Elderly patients: monitor closely for dizziness and falls.
• Concomitant CYP3A4 inhibitors: avoid or adjust dose when strong inhibitors are co‑administered.
• Store at room temperature: keep in the original packaging, protect from moisture and light.

Lercanidipine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Grapefruit juice: can markedly raise drug levels leading to hypotension.
• Other antihypertensives with additive blood‑pressure‑lowering effects: risk of severe hypotension.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect.
• Diuretics: may enhance orthostatic hypotension; monitor electrolytes.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive response.